|Presentation type||Oral presentation|
|Title||Prospective comparison between Cyclosporine eye drops dissolved in EvoTears® versus in castor oil in the treatment of ocular surface inflammatory diseases|
|Purpose||Cyclosporine A (CsA) eye drops are used in difficult ocular surface inflammatory diseases (OSID) and formulated in oil-based solvents (which are poorly tolerated) at the hospital pharmacy. This study aimed to compare the effectiveness and tolerance of CsA eye drops dissolved in Perfluorohexyloctane (H6F8 – CsA-H6F8) versus in castor oil (CO – CsA-CO) in order to obtain a new formulation feasible in public pharmacies and therefore more accessible to patients. The secondary objective was to determine the stability of CsA in H6F8.|
|Methods||This randomized double-blind monocentric study was conducted in the Ophthalmology department of Erasme Hospital. Main inclusion criteria was an OSID with a need of CsA and main exclusion criteria was pregnancy and/or breastfeeding. Eleven participants with allergic conjunctivitis (AC) and 2 with dry-eye-syndrome (DES) were included. Both eyes of each patient received daily for 4 consecutive weeks either CsA-H6F8 or CsA-CO. Effectiveness and tolerance were determined using different surface scores, photographs and a questionnaire, all performed before and after the treatment. CsA stability was determined by high-performance-liquid-chromatography/mass spectrometry.|
CsA-H6F8 showed a better effectiveness in AC but not for DES while the tolerance seems to be worse for CsA-H6F8. These differences were not statistically significant. CsA stability could not be determined due to aberrant results.
|Conclusion||Larger study and a longer follow-up might confirm these results. CsA stability might be determined using a UV-spectrophotometry. Future adjuvant is needed to increase the solubility and tolerance of CsA. An easier accessibility of CsA eye drops might decrease the overprescription of corticosteroids and its considerable side effects.|
|Conflict of interest||No|